Brand Name :
Yutopar
Synonyms :
ritodrine
Class :
Adrenergic Beta Agonists
Dosage Forms & Strengths
10mg/ml
15mg/ml
30mg/ml
Initial dose: 50 to 100 mcg intravenously (IV) per minute, increased as necessary by increments of 50 mcg every ten minutes to the dosage that balances uterine response and undesirable effects (increased maternal heart rate, decreased blood pressure, and increased fetal heart rate), or until the maternal heart rate reaches 130 beats per minute
Maintenance dose: The lowest dosage that keeps the uterus relaxed is 150 to 350 mcg intravenously each minute. ritodrine should be stopped if labor is uncontrollable or the maximum dose of 350 mcg per minute is reached, and labour continues
Safety and efficacy not established
Refer adult dosing
may increase the risk or severity of hypertension when combined
may decrease the therapeutic effect
may decrease the therapeutic effect
may decrease the therapeutic effect
may decrease the therapeutic effect
may decrease the therapeutic effect
it decreases the effect of antidiabetic drugs
it decreases the effect of antidiabetic drugs
it decreases the effect of antidiabetic drugs
may increase the risk or severity of hypertension when combined
may increase the risk or severity of hypertension when combined
may increase the risk or severity of hypertension when combined
may increase the risk or severity of hypertension when combined
may increase the risk or severity of hypertension when combined
may increase the risk or severity of hypertension when combined
may decrease the therapeutic efficacy when combined
may decrease the therapeutic efficacy when combined
may increase the risk or severity of hypertension when combined
may increase the risk or severity of hypertension when combined
may increase the risk or severity of hypertension when combined
may increase the risk or severity of hypertension when combined
may increase the risk or severity of hypertension when combined
may increase the risk or severity of hypertension when combined
may increase the risk or severity of hypertension when combined
may enhance the risk or severity of hypertension when combined
may enhance the risk or severity of hypertension when combined
may enhance the risk or severity of hypertension when combined
may enhance the risk or severity of hypertension when combined
may enhance the risk or severity of hypertension when combined
may enhance the risk or severity of hypertension when combined
may enhance the risk or severity of hypertension when combined
may enhance the risk or severity of hypertension when combined
may enhance the risk or severity of hypertension when combined
antidiabetic agents may have a reduced therapeutic effect when used together with ritodrine
antidiabetic agents may have a reduced therapeutic effect when used together with ritodrine
antidiabetic agents may have a reduced therapeutic effect when used together with ritodrine
may decrease the therapeutic effect of Anti-diabetic Agents
Mechanism of action
Its mechanism of action stimulates beta-2 adrenergic receptors in the uterus, which leads to smooth muscle relaxation, including the smooth muscle of the uterus
The relaxation of the uterine smooth muscle can help prevent contractions and delay the onset of labor. ritodrine also has a bronchodilator effect, which can help relieve respiratory distress in premature infants
Spectrum
The spectrum of activity of ritodrine is limited to its use in preventing premature labor. It is ineffective in treating labor that has already started or inducing labor in women at term. Ritodrine may be used alone or with other medications to help delay labor in high-risk pregnancies
Adverse Reaction:
Tachycardia (rapid heart rate)
Tremors
Headache
Nausea
Hypotension (low blood pressure)
Hyperglycemia (high blood sugar)
Pulmonary edema (fluid accumulation in the lungs)
Hypokalemia (low potassium levels)
Contraindications
Caution
Pregnancy consideration: Insufficient data available
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology
ritodrine is a medication classified as a beta-agonist, specifically a beta-2 selective agonist. It works by binding to beta-2 receptors in the smooth muscle of the uterus, causing relaxation of the uterus and delaying premature labor
Pharmacodynamics
In sympathetic neuroeffector junctions of several organs, including the uterus, beta-2 adrenergic receptors can be found. It is an agonist of beta-2 receptors. It activates the beta-2 adrenergic receptor, boosts cAMP, and lowers the amount of intracellular calcium. Premature uterine contractions are reduced as a result of the relaxing of the uterine smooth muscle caused by the drop in calcium concentration
Pharmacokinetics
Absorption
It can be administered via intravenous injection or oral tablet. When administered orally, ritodrine is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations reached within 30-60 minutes.
Distribution
It is distributed throughout the body, including crossing the placenta and entering breast milk. The volume of distribution is relatively small, indicating that it remains primarily in the plasma
Metabolism
It is metabolized by the liver, primarily by the enzyme cytochrome P450 3A4, to form inactive metabolites that are excreted in the urine
Elimination/Excretion
The elimination half-life of ritodrine is about 3-4 hours. It is excreted mainly in the urine, with a small portion also eliminated in the feces
Administration
ritodrine is a medication used to delay premature labor. It can be administered by intravenous injection or oral tablet. Here are some details about the administration of ritodrine:
Intravenous injection: When ritodrine is administered by intravenous injection, it is typically given as a continuous infusion. The initial dose of ritodrine is usually 50-100 mcg/min, gradually increasing until contractions are effectively suppressed, or the maximum recommended dose of 400 mcg/min is reached. The infusion rate is usually titrated based on the patient’s response and any potential side effects. Intravenous ritodrine is typically administered in a hospital setting under close monitoring
Oral tablet: ritodrine is available as an oral tablet in some countries but not in others. The recommended oral dose of ritodrine is usually 10-20 mg every 3-4 hours. The dose may be adjusted based on the patient’s response and any potential side effects
Patient information leaflet
Generic Name: ritodrine
Why do we use ritodrine?
ritodrine is a medication primarily used to delay premature labor. It works by relaxing the uterus muscles, which can help stop or slow down contractions.
Here are some of the specific uses of ritodrine: